drugset / Trial / NCT02158624

Summary

To establish the correlation between visual acuity improvement and QOL measurement after ranibizumab treatment for AMD patients.

Timeline

Start
2013-12
Primary completion
2015-04
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal